Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Abiraterone Acetate Treatment in Prostate Cancer

How does it affect survival?

Publish date:: December 8, 2015

Overall survival (OS) and radiographic progression-free survival (rPFS) trends demonstrate abiraterone acetate (AA) treatment benefit in patients with pre- or post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC) regardless of Gleason score at initial diagnosis. This according to a study of initial Gleason scores from 1,048 patients with mCRPC post-docetaxel and 996 patients with mCRPC who were chemotherapy-naïve. Researchers found:

• Baseline characteristics were similar across treatment groups.

• Regardless of Gleason score, AA treatment significantly improved rPFS in both treatment groups.

• Clinical benefit of AA treatment was also seen for OS, PSA response, objective response, and time to PSA progression across Gleason score subgroups.

Citation: Fizazi K, Flaig TW, Stӧckle M, et al. Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trials. [Published online ahead of print November 25, 2015]. Ann Oncol. doi: 10.1093/annonc/mdv545.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Genitourinary Cancer

Study shows no link between race and mortality in clear cell RCC,

Four factors may predict better survival with cabozantinib in mRCC,

Focal radiation boost nets better outcomes in prostate cancer,

Fear of recurrence highly prevalent in RCC survivors,

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,